Testing meldonium and tailored exercise in people with heart failure
Tests meldonium and personalized physical activity in adults with heart failure with preserved ejection fraction.
Key facts
- Who runs it
- Pauls Stradins Clinical University Hospital
- Where
- Riga, LatviaSee the site
- Trial code
- Registry title
- The role of meldonium and individualized physical activities in the treatment of patients with heart failure
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 200 people, planned
- Started
- 19 Jun 2024
- Expected to end
- 1 Dec 2029
- Type of study
- Interventional
- Record updated
- 27 March 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term heart failure with preserved ejection fraction. It tests meldonium and individual physical activity advice.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Chronic heart failure, NYHA class II-III. Left ventricle ejection fraction above 50 and LAVI above 34 ml/m2 on echocardiography.
- Earlier treatment
- On optimal medical therapy for at least 3 months. A coronary angiography or computed coronary angiography was done to rule out obstructive coronary artery disease. No digoxin, trimetazidine, ranolazine, meldonium or ivabradine. No coronary revascularisation within 3 months.
Main reasons for not taking part
- Allergic reaction to meldonium
- Iron deficiency anemia
- Severe kidney or liver disease
- Congenital heart disease, or moderate to severe heart valve disease
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Chronic heart failure II - III functional class NYHA (The New York Heart Association)
- In transthoracic echocardiography calculated left ventricle ejection fraction >50 un LAVI >34 ml/m2
- Patient receives optimal medical therapy for at least 3 months
- Coronary angiography or computed coronary angiography has been done to rule out obstructive coronary artery disease
- Patients ≥18 years
Who cannot take part
- Allergic reaction to meldonium
- Congenital heart diseases
- Moderate to severe cardiac valve diseases
- Iron deficiency anemia (men Hb < 13 g/dL, women Hb <12 g/dl un serum ferritin levels < 30ng/ml or transferrin saturation ≤19 %)
- Patient is involved in other trial
- Severe kindey or liver disfunction
- Pregnancy/breastfeeding women
- Patient uses digoxin, trimetazidine, ranolazine, meldonium, ivabradine
- Patient underwent coronary revascularisation within 3 months
Where in Latvia
- Pauls Stradins Clinical University HospitalRiga, LatviaTaking people
About the trial
What the trial wants to find out
To evaluate effectiveness of meldonium and individualised physical activity recommendations in patients with heart failure with preserved ejection fraction.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- The role of meldonium and individualized physical activities in the treatment of patients with heart failure
- Plain-language title
- Testing meldonium and tailored exercise in people with heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 27 March 2024